Reported 4 days ago
Gilead Sciences, Inc. (NASDAQ:GILD) has announced that it received marketing authorization from the European Commission for Yeytuo (lenacapavir), a twice-yearly injectable HIV-1 capsid inhibitor. This drug serves as a pre-exposure prophylaxis (PrEP) for adults and adolescents at high risk for HIV-1, making it the first and only option approved for use across the 27 EU member states. Gilead continues to focus on developing medicines for critical health needs across more than 35 countries.
Source: YAHOO
Reported 4 days ago
UBS has raised its price target for ConocoPhillips (NYSE:COP) from $116 to $123 while maintaining a Buy rating on the stock. This adjustment follows ConocoPhillips' fiscal Q2 2025 earnings announcement, where the company reported earnings per share of $1.56 and a strong cash flow. The company is recognized as a resilient low volatility stock in the oil and gas sector.
Source: YAHOO
Reported 4 days ago
Pfizer Inc. (NYSE:PFE) has received FDA approval for its supplemental Biologics License Application (sBLA) concerning the LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1), which is intended for adults 65 and older and younger individuals aged 5 to 64 with high-risk underlying conditions. The approval is based on extensive evidence showcasing the vaccine's safety and efficacy, including data from clinical trials for children aged 5 to 11.
Source: YAHOO
Reported 4 days ago
Bank of America Securities analyst Michael Funk has reiterated a Buy rating for AT&T Inc. (NYSE:T) with a price target of $34.00, citing the company's strong financial outlook and competitive positioning, particularly after its recent $23 billion acquisition of spectrum licenses from EchoStar. This acquisition is expected to enhance AT&T's broadband and wireless services, which are vital for its future growth. However, the report also mentions that certain AI stocks might present better investment opportunities.
Source: YAHOO
Reported 4 days ago
Verizon Communications Inc. (NYSE:VZ) is identified as a top undervalued stock with low volatility, as analyst Gregory Williams from TD Cowen maintains a Buy rating with a price target increase to $56. The company's management shows confidence in achieving EBITDA growth, bolstered by cost-saving strategies and strong service revenue. Additionally, Verizon’s AI integration in customer care is expected to enhance operational efficiency. Despite its potential, some analysts suggest other AI stocks may present better investment opportunities.
Source: YAHOO
Reported 4 days ago
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is currently viewed as a strong buy by analysts, with Bernstein's William Pickering maintaining a Buy rating and a price target of $95.00, while Evercore ISI's Cory Kasimov set a target of $110.00. The analyst consensus indicates a Strong Buy with a median price target suggesting a potential upside of 70.49%. The company focuses on developing treatments for serious and rare medical conditions.
Source: YAHOO
Reported 4 days ago
H.C. Wainwright has raised its price target for Summit Therapeutics Inc. (NASDAQ:SMMT) from $44 to $50, maintaining a Buy rating. The firm highlighted the positive results from Akeso’s HARMONi-A study, indicating that their drug ivonescimab outperforms Keytruda. Summit Therapeutics focuses on developing therapies for serious medical needs, particularly Clostridioides Difficile Infection (CDI).
Source: YAHOO
Reported 4 days ago
Citizens JMP analyst Andrew Boone has reiterated a Buy rating on Wix.com Ltd. (NASDAQ:WIX) with a price target of $200.00, following positive fiscal Q2 2025 results that highlighted significant revenue growth and strong bookings. The company's cloud-based website design platform continues to gain traction, evidenced by a 14% year-over-year increase in new cohort bookings. While Wix presents a solid investment opportunity, some analysts suggest that certain AI stocks may offer better upside potential.
Source: YAHOO
Reported 4 days ago
Canaccord Genuity analyst Joseph Vafi has reaffirmed a Buy rating for Strategy Inc. (NASDAQ:MSTR), setting a price target of $464. He noted that the company's recent preferred stock sales, which raised over $6 billion this year, highlight its success in the capital markets. Despite Bitcoin's volatility posing risks, Vafi considers MSTR to be one of the most innovative companies in his coverage, predicting an increase in firms adopting its Bitcoin-driven treasury strategy.
Source: YAHOO
Reported 4 days ago
Jefferies analyst Tycho Peterson reaffirmed a Buy rating on Exact Sciences Corporation (NASDAQ:EXAS) on August 21, with a price target set at $80.00. The company reported a record revenue of $811 million for Q2 2025, a 16% increase, and raised its revenue guidance. Exact Sciences specializes in cancer detection and offers tests like Cologuard for colorectal cancer screening. Despite its investment potential, some analysts suggest AI stocks may offer better returns.
Source: YAHOO
Reported 4 days ago
Stifel Nicolaus has reaffirmed its Buy rating for HubSpot, Inc. (NYSE:HUBS), setting a price target of $650 following the company's strong Q2 2025 earnings, which showed a 19% increase in total revenue to $760.9 million compared to the previous year. The report highlighted the company's solid subscription revenue growth and the innovative features of its software products designed for inbound marketing, customer service, and sales.
Source: YAHOO
Reported 4 days ago
Teva Pharmaceutical Industries Limited has announced the FDA approval and U.S. launch of Generic Saxenda, the first generic GLP-1 medication for weight loss, aimed at addressing the increasing demand in the U.S. market. This product is designed for adults with obesity and adolescents aged 12-17 who are overweight. This launch marks Teva's fifth first-to-market generic entry this year, further establishing its robust generics portfolio.
Source: YAHOO
Reported 4 days ago
BofA analyst Wamsi Mohan has reduced the price target for Nutanix, Inc. (NASDAQ:NTNX) from $95 to $93 while maintaining a Buy rating. The adjustment follows the company's strong fiscal Q4 results, which exceeded expectations, although a conservative outlook for fiscal year 2026 is anticipated. Despite the price target reduction, Nutanix has consistently surpassed operating margin guidance by a significant margin over the past three years.
Source: YAHOO
Reported 4 days ago
Argus has initiated coverage of DexCom, Inc. (NASDAQ:DXCM) with a Buy rating and a price target of $100. The firm expects DexCom to maintain strong growth above the industry average, increase profitability through cost leverage, and expand its customer base in the continuous glucose monitoring market for diabetes management. DexCom's robust free cash flow enables significant R&D investments for product innovation. The current share price is seen as an attractive entry point for investors.
Source: YAHOO
Reported 4 days ago
Wells Fargo analyst Michael Berg has maintained a Hold rating on monday.com Ltd. (NASDAQ:MNDY) without setting a price target, following the company's impressive fiscal Q2 2025 results, which showed a 27% revenue increase year-over-year to $299 million. The firm reported a record number of new customers and significant growth in its CRM segment. However, Wells Fargo suggests that while MNDY is a viable investment, other AI stocks may present better upside potential with reduced risks.
Source: YAHOO
Reported 4 days ago
Merck & Co. (MRK) has announced the dosing of the first patient in its HERTHENA-Breast04 phase 3 trial, which aims to assess the efficacy and safety of patritumab deruxtecan in treating patients with advanced hormone receptor-positive, HER2-negative breast cancer. This drug, developed in collaboration with Daiichi Sankyo, targets specific cancer treatments following previous therapies.
Source: YAHOO
Reported 4 days ago
Source: WSJ
Reported 4 days ago
Source: WSJ
Reported 4 days ago
In the lead-up to Labor Day, the national Outbound Tender Volume Index (OTVI) for truckload demand saw a significant increase of 6.5%, marking a notable surge compared to previous years. This rise is attributed to the market recovering from a low in August and suggests that shippers might be facing leaner inventory levels than planned. Despite challenges from intermodal competition, the demand for long-haul trucking has risen unexpectedly early this year, prompting potential shifts in capacity and rates. While this increase does not signal a complete market recovery, it highlights the precarious nature of supply and demand dynamics as we approach the peak season.
Source: YAHOO
Reported 4 days ago
CoreWeave, Inc. (NASDAQ:CRWV), recognized as a leading AI stock, has been assigned an Overweight rating by Cantor Fitzgerald analyst Thomas Blakey, along with a price target of $116. The firm expresses optimism about CoreWeave's potential, citing its position to capitalize on the expanding AI market, particularly in large language model training and usage. Despite the positive outlook, the report advises caution, indicating that other AI stocks might offer greater long-term benefits with lower risks.
Source: YAHOO
Reported 4 days ago
Wells Fargo has reaffirmed its 'Overweight' rating on CrowdStrike Holdings, Inc. (NASDAQ:CRWD), highlighting the company's strong performance in its latest quarterly results and optimistic guidance for the second half of 2026. Key drivers of growth include a successful Falcon Flex program and strategic acquisitions. Despite recognizing CRWD's potential, Wells Fargo notes that some other AI stocks may offer greater upside with less risk.
Source: YAHOO
Reported 4 days ago
Raymond James has upgraded Snowflake Inc.'s price target to $230 after the company exceeded revenue expectations for fiscal year 2026, reporting $1.14 billion in revenue and adjusted EPS of $0.38. The company raised its full-year product revenue guidance to $4.395 billion, indicating a 27% year-over-year growth. CEO Sridhar Ramaswamy emphasized Snowflake's leading position in AI data platforms, stating it is the best in the sector. Following these positive announcements, shares rose approximately 10% in after-hours trading.
Source: YAHOO
Reported 4 days ago
Cantor Fitzgerald analyst Matthew VanVliet has reiterated an Overweight rating for Salesforce (CRM) with a price target of $325 ahead of the upcoming earnings report on September 3rd. The firm anticipates growth in areas such as Data Cloud and Agentforce, while noting expected challenges in Marketing and Commerce Cloud sectors. Recent discussions indicate a potential expansion of AI-powered Agentforce projects, with 40% of customers likely to increase their deployment in the next year.
Source: YAHOO
Reported 4 days ago
Broadcom Inc. (NASDAQ:AVGO) has been recognized as the 'no. 2 AI franchise' after Nvidia, according to Oppenheimer analysts who reaffirmed a positive outlook for the stock ahead of earnings on September 4. They highlighted Broadcom's leadership in the AI ASIC market and noted its continued growth fueled by AI compute and networking sectors, with significant projects led by major companies like Google, Meta, and ByteDance USA. Analysts raised the price target to $325, emphasizing Broadcom's potential for sustainable growth.
Source: YAHOO
Reported 4 days ago
Nvidia Corporation (NASDAQ: NVDA) remains a prominent player in the AI sector, with William Blair analyst Sebastien Naji reaffirming an Outperform rating despite ongoing uncertainties around China export licenses. The company's recent earnings report indicated modest improvements, driven by its Blackwell Ultra product, which generated over $10 billion in revenue. Analysts expect Nvidia to maintain its AI leadership and robust growth potential into fiscal 2026, despite the stock's minor decline in after-hours trading.
Source: YAHOO